Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

15.4%

2 terminated out of 13 trials

Success Rate

71.4%

-15.1% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed with results

Key Signals

71% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (7)
P 1 (2)
P 2 (2)

Trial Status

Completed5
Recruiting3
Terminated2
Unknown2
Active Not Recruiting1

Trial Success Rate

71.4%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07213154Not ApplicableRecruiting

Optical Imaging Scans for the Diagnosis of Skin Cancer in Patients With Lesions

NCT07062003Not ApplicableRecruiting

Minibeam Radiation Therapy With Tungsten Slit Collimator for the Treatment of Recurrent or Metastatic Skin or Soft Tissue Tumors, MBRT1 Trial

NCT05786716Phase 2Recruiting

DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations

NCT05908435Not ApplicableActive Not RecruitingPrimary

Impact of Sunscreen Dispensers in Parks Visited by Teenagers

NCT05788939Not ApplicableCompletedPrimary

PLANNED VISUAL EDUCATION ABOUT SKIN CANCER

NCT05068687Not ApplicableCompleted

Peroperative Assessment of Malignancies of the Head and Neck Using High-resolution 18F-FDG-PET/CT

NCT02580916Not ApplicableCompletedPrimary

Utility of the Skin Cancer Quality of Life Impact Tool

NCT03321903Terminated

EPR Tumor Oximetry With CE India Ink

NCT04176237Not ApplicableCompletedPrimary

School-based Randomized Trial of SunSmart Interventions

NCT02602067Phase 1Terminated

131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

NCT03666325Phase 2UnknownPrimary

Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance

NCT01167998Unknown

Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions

NCT02550678Phase 1Completed

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma

Showing all 13 trials

Research Network

Activity Timeline